TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29559423

Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29559561

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 29559773

Group type: EXPERIMENTAL
Intervention: Statistical modeling approaches to define distinct disease groups in patients with obstructive lung disease using medical history and spirometric data.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical modeling approaches (asthma model, COPD model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PLS-DA
Number of subjects: 0
Study: 29560093

Group type: EXPERIMENTAL
Intervention: Bevacizumab-based chemotherapy
Number of subjects: 43
Study: 29560379

Group type: COMPARATOR
Intervention: Baseline normalized brain volume (high)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brain volume loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline T2 lesion volume
Number of subjects: 0
Study: 29560743

Group type: EXPERIMENTAL
Intervention: Liletta (levonorgestrel 52 mg IUS)
Number of subjects: 0
Study: 29561066

Group type: EXPERIMENTAL
Intervention: IdeS (imlifidase) 0.12 mg/kg body weight ×2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IdeS (imlifidase) 0.25 mg/kg ×1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IdeS (imlifidase) 0.25 mg/kg ×2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IdeS (imlifidase)
Number of subjects: 8
Study: 29561219

Group type: EXPERIMENTAL
Intervention: Acute reperfusion therapies including thrombectomy and thrombolysis in the acute phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline characteristics including rate of thrombolysis in acute stroke
Number of subjects: 0

Group type: COMPARATOR
Intervention: Key performance indicators in secondary prevention
Number of subjects: 0
Study: 29561296

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (≤4 ml 10 PFU/ml; administered on day 1 and every 2 weeks thereafter)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Number of subjects: 2
Study: 29562804

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Atezolizumab
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 1125
Study: 29562855

Group type: EXPERIMENTAL
Intervention: RectroNectin-activated cytokine-induced killer (R-CIK) cell immunotherapy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (chemotherapy only)
Number of subjects: 125
Study: 29562895

Group type: EXPERIMENTAL
Intervention: GDM classified by the 2013 WHO criteria
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Women without GDM by both criteria
Number of subjects: 1092
Study: 29562937

Group type: EXPERIMENTAL
Intervention: Intermittent renal replacement therapy (IRRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 0
Study: 29563196

Group type: EXPERIMENTAL
Intervention: Islet transplantation
Number of subjects: 0
Study: 29563634

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 131

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 131
Study: 29563837

Group type: EXPERIMENTAL
Intervention: Clinical predictive model using random forest, genetic algorithms, and classification and regression trees.
Number of subjects: 1945

Group type: EXPERIMENTAL
Intervention: Risk categorization using the decision tree model.
Number of subjects: 1945

Group type: EXPERIMENTAL
Intervention: Optimal cut-off point of estimated risk.
Number of subjects: 1945
Study: 29563871

Group type: EXPERIMENTAL
Intervention: Naltrexone and Bupropion combination treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29564045

Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone/naloxone at a starting dose of 10/5 mg/day (maximum 80/40 mg/day) for 8 weeks
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone/naloxone
Number of subjects: 209
Study: 29564161

Group type: EXPERIMENTAL
Intervention: Indoor residual spraying (IRS) with microencapsulated pirimiphos-methyl (Actellic 300 CS) once a year for 2 years, in addition to long-lasting insecticide-treated nets (LLINs).
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Long-lasting insecticide-treated nets (LLINs) only.
Number of subjects: 1548

Group type: EXPERIMENTAL
Intervention: IRS intervention (pirimiphos-methyl) and LLINs.
Number of subjects: 1548
Study: 29564726

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilatory support with lower maximum airway pressure
Number of subjects: 935

Group type: COMPARATOR
Intervention: Patients who died
Number of subjects: 935
Study: 29564996

Group type: COMPARATOR
Intervention: Placebo (control group from clinical trials NCT00241644 and NCT00362648)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early antibiotic use
Number of subjects: 0
Study: 29565018

Group type: EXPERIMENTAL
Intervention: Vulnerable patients (Clinical Frailty Score 3 or 4)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Frail patients (Clinical Frailty Score 5 or 6)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Overall frailty (including vulnerable and frail classifications)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Geriatric consultation (only 10 patients received this)
Number of subjects: 308
Study: 29565190

Group type: EXPERIMENTAL
Intervention: GenPs prevalence at the time of enrollment in two prospective randomized phase 3b trials (NCT02561806 and NCT02634801)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GenPs prevalence reported in literature
Number of subjects: 0
Study: 29565424

Group type: EXPERIMENTAL
Intervention: 4,000 L rhGAA
Number of subjects: 113
Study: 29565961

Group type: EXPERIMENTAL
Intervention: Real-time fluoroscopy (RTF)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 128
Study: 29566106

Group type: EXPERIMENTAL
Intervention: Avelumab, 10 mg/kg, by 1-hour intravenous infusion every 2 weeks until disease progression or unacceptable toxic effects.
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Avelumab treatment
Number of subjects: 39
Study: 29566186

Group type: EXPERIMENTAL
Intervention: Red and processed meat intake (10 g/d)
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Cereal intake (50 g/d)
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Dietary fiber intake (10 g/d)
Number of subjects: 2586
Study: 29566185

Group type: EXPERIMENTAL
Intervention: Monounsaturated fats from plant sources (MUFA-P)
Number of subjects: 93484

Group type: EXPERIMENTAL
Intervention: Monounsaturated fats from animal sources (MUFA-A)
Number of subjects: 93484

Group type: EXPERIMENTAL
Intervention: Replacement of the sum of MUFA-As and SFAs (5% of energy) with MUFA-Ps
Number of subjects: 93484
Study: 29566190

Group type: EXPERIMENTAL
Intervention: Earlier introduction of complementary food (<4 mo old)
Number of subjects: 36481

Group type: EXPERIMENTAL
Intervention: Protein intake from dairy products (per 5 g/d)
Number of subjects: 36481

Group type: EXPERIMENTAL
Intervention: Protein intake from meat and fish (per 2 g/d)
Number of subjects: 36481
Study: 29566195

Group type: EXPERIMENTAL
Intervention: Serum formate concentrations
Number of subjects: 1701

Group type: COMPARATOR
Intervention: Gender (women)
Number of subjects: 1701

Group type: EXPERIMENTAL
Intervention: TT genotype of MTHFR 677C→T (rs1801133) polymorphism
Number of subjects: 1701

Group type: EXPERIMENTAL
Intervention: Potential metabolic precursors (serine, methionine, tryptophan, choline)
Number of subjects: 1701

Group type: EXPERIMENTAL
Intervention: Serum folate
Number of subjects: 1701

Group type: EXPERIMENTAL
Intervention: Serum vitamin B-12
Number of subjects: 1701
Study: 29566201

Group type: COMPARATOR
Intervention: Formal employment
Number of subjects: 184548

Group type: COMPARATOR
Intervention: Informal employment
Number of subjects: 184548

Group type: EXPERIMENTAL
Intervention: Nonemployment
Number of subjects: 184548
Study: 29566246

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (300 mg/120 mg) for 8 weeks in noncirrhotic patients and 12 weeks in cirrhotic patients.
Number of subjects: 153
Study: 29566654

Group type: EXPERIMENTAL
Intervention: Video-oculography (VOG) with alternate cover
Number of subjects: 34

Group type: COMPARATOR
Intervention: Alternate prism cover test (APCT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Video-oculography (VOG)
Number of subjects: 34
Study: 29566656

Group type: EXPERIMENTAL
Intervention: blended cognitive behavioral therapy (b-CBT) consisting of three face-to-face sessions and eight online sessions
Number of subjects: 156

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 156
Study: 29566673

Group type: EXPERIMENTAL
Intervention: Grip strength measurement implementation training for nursing staff
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Grip strength measurement
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Implementation of grip strength measurement
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Training and implementation of grip strength measurement
Number of subjects: 155
Study: 29566688

Group type: EXPERIMENTAL
Intervention: Educational intervention consisting of five seminars over 6 months for staff and managers in nursing homes.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 20
Study: 29566698

Group type: EXPERIMENTAL
Intervention: Oral health intervention program from infancy to age 5 years.
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group of children with CHD who did not receive the program, born 2005-2007.
Number of subjects: 119
Study: 29566699

Group type: EXPERIMENTAL
Intervention: Integrative analysis of GWAS and gene expression
Number of subjects: 0
Study: 29566732

Group type: EXPERIMENTAL
Intervention: Multiple-level stakeholder engagement measures including local meetings with community leaders and engagement with family members of prospective trial participants.
Number of subjects: 0
Study: 29566730

Group type: EXPERIMENTAL
Intervention: Strengthened training in depression components of PC101 and clinical communication skills for nurse-led chronic care, with a facility-based behavioural health counsellor providing structured manualised counselling for depression.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard training in Primary Care 101 (PC101) for integrated chronic care including guidelines for hypertension and depression care.
Number of subjects: 1000
Study: 29566744

Group type: EXPERIMENTAL
Intervention: Combined Exercise and ACT programme
Number of subjects: 160

Group type: COMPARATOR
Intervention: Supervised exercise classes (Control)
Number of subjects: 160
Study: 29566762

Group type: EXPERIMENTAL
Intervention: CyberKnife accelerated partial breast irradiation (CK-APBI) with 30 Gy in five fractions, treatment time approximately 60 min (range 35 to 120 min).
Number of subjects: 20
Study: 29566766

Group type: EXPERIMENTAL
Intervention: Customized tele-rehabilitation platform (GNPT)
Number of subjects: 0
Study: 29566812

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 287
Study: 29566820

Group type: EXPERIMENTAL
Intervention: Preterm-born individuals
Number of subjects: 101
Study: 29567071

Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil-based chemotherapy after D2 gastrectomy (n=193)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Surgery alone (n=114)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy plus surgery (n=323)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Surgery alone (n=302)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Predictive single patient classifier (based on GZMB, WARS, and CDX1)
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: Predictive single patient classifier (based on GZMB, WARS, and SFRP4)
Number of subjects: 932
Study: 29567461

Group type: EXPERIMENTAL
Intervention: PrEP-001
Number of subjects: 0
Study: 29567632

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg orally twice daily
Number of subjects: 20
Study: 29567667

Group type: EXPERIMENTAL
Intervention: Acupuncture for insomnia
Number of subjects: 0
Study: 29567774

Group type: EXPERIMENTAL
Intervention: Lenalidomide, dosage and duration not available
Number of subjects: 0
Study: 29567781

Group type: EXPERIMENTAL
Intervention: Novel regimen for relapsed/refractory adult acute myeloid leukemia
Number of subjects: 0
Study: 29567784

Group type: EXPERIMENTAL
Intervention: Treatment until focal lesion signal suppression
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Continued treatment post day 7
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Presence of more than 3 focal lesions at presentation
Number of subjects: 596
Study: 29567785

Group type: EXPERIMENTAL
Intervention: DNA polymerase ν gene expression
Number of subjects: 99
Study: 29567798

Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 0
Study: 29567858

Group type: EXPERIMENTAL
Intervention: Higher serum bicarbonate levels
Number of subjects: 2853
Study: 29568374

Group type: EXPERIMENTAL
Intervention: Folate receptor-targeted intraoperative molecular imaging (FR-IMI) with OTL38
Number of subjects: 12
Study: 29568762

Group type: EXPERIMENTAL
Intervention: Patients with epilepsy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study: 29569246

Group type: EXPERIMENTAL
Intervention: 3T3-J2 feeder cell culture with Y-27632 (ROCK inhibitor) in conditional reprograming conditions (CRC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12
Study: 29569311

Group type: EXPERIMENTAL
Intervention: Transperineal targeted prostate biopsy
Number of subjects: 32
Study: 29569385

Group type: EXPERIMENTAL
Intervention: Taste dysfunction assessment using validated taste strips for sweet, sour, salty, and bitter; olfactory testing using the Sniffin' Sticks Test; endoscopic evaluation using Lund-Kennedy and OCES systems.
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) surveys related to taste, smell, overall sinus-specific QOL, and depression.
Number of subjects: 68
Study: 29570248

Group type: EXPERIMENTAL
Intervention: Short-term overfeeding (OF)
Number of subjects: 21
Study: 29570897

Group type: EXPERIMENTAL
Intervention: Broad definition of on-label prescribing
Number of subjects: 4519

Group type: EXPERIMENTAL
Intervention: Restrictive definition excluding patients with conditions for which dabigatran is not indicated
Number of subjects: 4519
Study: 29570971

Group type: EXPERIMENTAL
Intervention: CYP2C19 and escitalopram
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CYP2D6 and fluoxetine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CYP2C19 and sertraline
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CYP2D6 and O-desmethylvenlafaxine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CYP2B6 and sertraline
Number of subjects: 64
Study: 29571565

Group type: EXPERIMENTAL
Intervention: Genetic influences on food timing
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Timing of breakfast
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Timing of lunch
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Timing of dinner
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Wake time
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bedtime
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bivariate analyses of food timing and bedtime/chronotype
Number of subjects: 106
Study: 29571601

Group type: EXPERIMENTAL
Intervention: Increased proportion of circulating CD4 T-lymphocytes
Number of subjects: 0
Study: 29571602

Group type: EXPERIMENTAL
Intervention: Norwood procedure
Number of subjects: 461
Study: 29571854

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg three times a week
Number of subjects: 150

Group type: COMPARATOR
Intervention: Glatiramer acetate 20 mg daily
Number of subjects: 150
Study: 29571946

Group type: EXPERIMENTAL
Intervention: Nilotinib (400 mg twice per day)
Number of subjects: 56
Study: 29572283

Group type: EXPERIMENTAL
Intervention: Cerebellar volume loss
Number of subjects: 70
Study: 29572391

Group type: EXPERIMENTAL
Intervention: Infusion of donor-derived CD8
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29572709

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg/m for at least 6 months
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination therapy with everolimus 10 mg/d
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pasireotide alone and with everolimus
Number of subjects: 19
Study: 29573215

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study: 29573876

Group type: EXPERIMENTAL
Intervention: Tdap
Number of subjects: 175

Group type: COMPARATOR
Intervention: Td
Number of subjects: 175
Study: 29573889

Group type: EXPERIMENTAL
Intervention: Broccoli sprouts (30 g/day) for 10 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal diet without broccoli sprouts for 10 weeks
Number of subjects: 40
Study: 29574070

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg/d)
Number of subjects: 12
Study: 29574465

Group type: EXPERIMENTAL
Intervention: Oral HIV test
Number of subjects: 334
Study: 29574497

Group type: EXPERIMENTAL
Intervention: Patients with CKD (albuminuria ≥ 30 mg/day)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Patients aged < 55 years with worse albuminuria or eGFR category
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Patients aged ≥ 75 years with albuminuria < 10 mg/day
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Higher albuminuria and lower eGFR (even in normal range)
Number of subjects: 15773
Study: 29574622

Group type: EXPERIMENTAL
Intervention: 7.5 mg/week MTX + adalimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg/week MTX + adalimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab initiation
Number of subjects: 0
Study: 29574635

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 50 (LM50)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Insulin lispro mix 25 (LM25)
Number of subjects: 156
Study: 29574916

Group type: EXPERIMENTAL
Intervention: Rehabilitation interventions targeting functional capabilities and home environment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Pre-PICU functional status and capabilities
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Home environmental support
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 180
Study: 29575698

Group type: EXPERIMENTAL
Intervention: Hypoxic training (3,000 m, n=12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normoxic training (n=11)
Number of subjects: 23
Study: 29575771

Group type: EXPERIMENTAL
Intervention: Patients with cancer (C-WL)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study: 29576119

Group type: EXPERIMENTAL
Intervention: US patients
Number of subjects: 14334

Group type: COMPARATOR
Intervention: International patients
Number of subjects: 14334
Study: 29576127

Group type: EXPERIMENTAL
Intervention: PEEP-step method (PSM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional method using oesophageal pressure (PES) measurements
Number of subjects: 24
Study: 29576258

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29576341

Group type: EXPERIMENTAL
Intervention: Human bone marrow-derived stem cells (BMDSCs) infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion of BMDSCs and their CD133+ fraction
Number of subjects: 0
Study: 29576550

Group type: EXPERIMENTAL
Intervention: Lipoprotein B (Lp-B)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Apo-B
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Apo-C-III-HP
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Apo-C-III (total)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Lp-A1:AII
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Apo-A1
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Triacylglycerols
Number of subjects: 417
Study: 29577029

Group type: EXPERIMENTAL
Intervention: Peg-interferon Alfa-2a
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nucleos(t)ide Analog
Number of subjects: 0
Study: 29577674

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 110
Study: 29578248

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 1451

Group type: COMPARATOR
Intervention: Bupivacaine dosage
Number of subjects: 1451

Group type: COMPARATOR
Intervention: Gender, ASA-score, height, weight, BMI, THA vs. TKA
Number of subjects: 1451
Study: 29578249

Group type: EXPERIMENTAL
Intervention: High preoperative serum 25-hydroxyvitamin D concentration
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Preoperative vitamin D deficiency
Number of subjects: 123

Group type: COMPARATOR
Intervention: Nonsurgical control subjects
Number of subjects: 123
Study: 29578250

Group type: EXPERIMENTAL
Intervention: Vasopressin infusion 4.8 U/h
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vasopressin infusion combined with nitroglycerin infusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Vasopressin alone
Number of subjects: 13
Study: 29578646

Group type: EXPERIMENTAL
Intervention: Lamotrigine 25 to 100 mg once daily
Number of subjects: 16
Study: 29579214

Group type: EXPERIMENTAL
Intervention: Temocillin 1, 2 or 3 g (total of 61 doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: New temocillin dosage regimen (not specified in detail)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Currently licensed dosage regimen
Number of subjects: 16
Study: 29579325

Group type: EXPERIMENTAL
Intervention: veliparib plus temozolomide
Number of subjects: 50
Study: 29579331

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily
Number of subjects: 39
Study: 29579370

Group type: EXPERIMENTAL
Intervention: Catastrophizing (CAT) statements during fMRI
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Catastrophizing (CAT) statements
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clinical pain severity
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neutral (NEU) statements during fMRI
Number of subjects: 31
Study: 29579597

Group type: EXPERIMENTAL
Intervention: Exercise hyperventilation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test
Number of subjects: 18
Study: 29579607

Group type: EXPERIMENTAL
Intervention: WAMI Score
Number of subjects: 6986